## In the Specification

On page 4 please amend paragraphs 1, 2 and 3 to read as follows:

According to the invention parvovirus NS1 variants are preferred in which the shift of equilibrium is achieved by mutation of one or several phosphorylation sites. Particularly preferred are parvovirus NS1 variants that have a mutation at one or several of the phosphorylation sites 283, 363, 394 and 463. Even more preferred are the parvovirus NS1 variants S283A (SEQ ID NO. 6 [4]), T363A (SEQ ID NO.10 6), T394A (SEQ ID NO. 14 8) and T463A (SEQ ID NO. 18 10), which are indicated in Table 1 and [figure 1] figures 1.1, 1.2, 1.3 and 1.4. In S283A, a serine is exchanged by an alanine at position 283, in T363A, a threonine is exchanged by alanine at position 363, in T394A a threonine is exchanged by alanine at position 394 and in T463A a threonine is exchanged by alanine at position 463.

A further subject matter of the present invention relates to a nucleic acid, particularly a DNA, which codes for an above parvovirus NS1 variant. Such a DNA comprises preferably:

- (a) the DNA of fig. 1.1 (SEQ ID NO.  $\underline{4}$  3), 1.2 (SEQ ID NO.  $\underline{8}$  5), 1.3 (SEQ ID NO.  $\underline{12}$  7) and 1.4 (SEQ ID NO.  $\underline{16}$  9), respectively
- (b) a DNA hybridizing with the DNA from (a), said DNA comprising the mutated phosphorylation site of the DNA from (a), or
- (c) a DNA related to the DNA from (a) or (b) via the degenerated genetic code.

The DNA of (a) was deposited with DSMZ (Deutsche Sammlung von ikroorganismen and Zellkulturen) on Aug. 11 1999, i.e. fig. 1.1 as Escherichia coli pRSV-NS: S283A under DSM 12994 (SEQ ID NO. 4 3), fig. 1.2 as Escherichia coli pRSV-NS: T363A under DSM 12995 (SEQ ID NO. 8 5), fig. 1.3 as Escherichia coli pRSV-NS: T394A under DSM 12996 (SEQ ID NO: 127) and fig. 1.4 as Escherichia coli pRSV-NS: T463A under DSM 12997 (SEQ ID NO. 169).

On page 7, please amend the last full paragraph to read as follows:

Fig. 1 shows the DNA and amino acid sequences of parvovirus NS1 variants according to the invention (fig. 1.1 (SEQ ID Nos.  $\underline{4}$  2 and  $\underline{6}$  [4]), 1.2 (SEQ ID Nos.  $\underline{8}$  5 and  $\underline{10}$  6), 1.3 (SEQ ID Nos.  $\underline{12}$  [7] and  $\underline{14}$  8) and 1.4 (SEQ ID Nos.  $\underline{16}$  9 and  $\underline{18}$  40)) as compared to parvovirus NS1 wild type (SEQ ID Nos. 1 and 2). In this connection, the mutated sites in the parvovirus Ns 1 variants according to the invention are labeled each.